The Evolving Management of Heart Failure: A Focus on Managed Care Recommendations Web Activity

• Chapter 1: Integrating Novel Therapies and Recent Evidence for HF into Plan Algorithms and Management Strategies
  
• Chapter 2: Multidisciplinary Collaborations and Interventions for Optimal Access to Care
  • Release Date: March 30, 2020
  • Expiration Date: September 30, 2021
  • Estimated Time to Complete Activity:
  • Chapter 1: 0.5 hour
  • Chapter 2: 0.75 hour
  • Compatible with all modern browsers and mobile devices

EXPERT FACULTY

Akshay S. Desai, MD, MPH                                   Director, Heart Failure Disease Management Program, Advanced Heart Disease Section, Cardiovascular Division Brigham and Women's Hospital Associate Professor of Medicine Harvard Medical School Click here for biography Jeffrey Dunn, PharmD, MBA                                                     (Formerly) Vice President, Clinical Strategy and                          Programs and Industry Relations                                   Magellan Rx Management Click here for biography John Fox, MD, MHA Vice President of Clinical Transformation Executive Medical Director, West Michigan ACO Spectrum Health Systems Click here for biography

Target Audience

• Managed care pharmacy directors, clinical pharmacists, quality directors, medical directors
• Pharmacy directors, specialty pharmacists, quality directors, care managers, registered nurses, and other managed care and payer organization professionals

Statement of Need/Program Overview
The body of evidence supporting the use of emerging therapies in heart failure (HF) is constantly evolving. Recent findings among patients hospitalized with acute decompensated HF demonstrate the potential for a simpler treatment algorithm for inpatient care. In addition to negating the transition period necessary between therapies, hospitalized patients represent a captive audience and one that can be more easily educated and monitored for adherence. These and other considerations will be addressed by this activity including additional clinical trial results.

Educational Objectives 
At the conclusion of this activity, participants should be able to demonstrate improved ability to: 

1. Module 1
1. Integrate novel therapies for HF into plan algorithms and utilization management strategies in light of published evidence and provider inertia
2. Module 2
1. Illustrate opportunities to overcome barriers to member access to care along with appropriate HF therapy within the current framework of health plan operations and infrastructure
2. Employ collaborative strategies for HF management, including overseeing care transitions, enlisting the input and support of a multidisciplinary team of health care providers

ACCREDITATION
Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC®.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Chapter 1: 0.5 CME credit
Chapter 2: 0.75 CME credit

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hours (.125 CEU) of the Accreditation Council for Pharmacy Education.
Chapter 1: UAN: JA4008162-9999-20-2035-H01-P, 0.5 contact hour (Knowledge)
Chapter 2: UAN: JA4008162-9999-20-2036-H01-P, 0.75 contact hour (Knowledge)

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.2 contact hours.
Chapter 1: 0.5 contact hour
Chapter 2: 0.7 contact hour

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change. Chapter 1: 0.5 IPCE credit Chapter 2: 0.75 IPCE credit

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The PIM planners and managers have nothing to disclose.
The Impact Education, LLC^® planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the accreditation period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, a certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account. Credit must be uploaded to CPE Monitor within 30 days.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.